Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

Bristol-Myers Squibb (SMY) stock falls as its Q4 2024 results beat Street forecasts, but its 2025 outlook fell short of ...

The 2025 forecast reflects a revenue hit of about 18% to 20% to the company's legacy portfolio from the near-term effects of generics on cancer drugs Revlimid, Pomalyst, Sprycel and Apraxane. The ...

Looking at Bristol-Myers Squibb Company's (NYSE:BMY ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by ...

Ratings for Bristol-Myers Squibb BMY were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ...

Bristol Myers Squibb (BMY) ended the recent trading session at $60.62, demonstrating a +1.59% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily ...

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced in Q4 CY2024, with sales up 7.5% year on year to $12.34 ...

David Risinger’s rating is based on the impressive launch performance of Bristol-Myers Squibb’s Cobenfy, which is showing strong sales momentum since its introduction for schizophrenia treatment.

We recently published a list of Jim Cramer Tells Viewers To Not Trust Billionaires & Discusses These 11 Stocks. In this ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Bristol Myers Squibb (BMY) reports results for the quarter ended December 2024. While this widely-known consensus ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other safe stocks to buy for the long term in 2025. The US stock market is often ...